Updated Severity and Prognosis Score of Pulmonary Alveolar Proteinosis

NCT04516577 | Completed

• 1 other identifier: 2020073195
• Study Type: observational
• Target: 231
• Locations: 1 country
• Sites: 1

Brief Summary

By updating the chest HRCT scoring criteria of patients with pulmonary alveolar proteinosis, a new and more perfect system for evaluating the severity of alveolar proteinosis will be established.

Conditions

Pulmonary Alveolar Proteinosis

Outcome Measures

Primary Outcomes (1)

• The severity and prognosis of pulmonary alveolar proteinosis

  The second severity and prognosis score of PAP (SPSP II) involves the range and density of lesion in chest CT of patients

  From July 2020 to December 2021

Study Arms (3)

Shanghai Pulmonary Hospital

Shanghai Pulmonary Hospital is a hospital specializing in the treatment of lung diseases. Many patients with pulmonary alveolar proteinosis receive treatment in this hospital.

Other: Assesssing the severity of pulmonary alveolar proteinosis

Peking Union Medical College Hospital

Peking Union Medical College Hospital is a famous hospital in China. Many patients with rare pulmonary disease receive treatment in this hospital.

Other: Assesssing the severity of pulmonary alveolar proteinosis

Nanjing Drum Tower Hospital

The Department of Respiratory and Critical Care Medicine of Nanjing Drum Tower Hospital has been focusing on the research of rare pulmonary diseases for many years.

Interventions

Assesssing the severity of pulmonary alveolar proteinosis OTHER

Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.

Peking Union Medical College Hospital; Shanghai Pulmonary Hospital

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis. Every patient had a complete medical history, chest HRCT, pulmonary function and arterial blood gas analysis.

You may qualify if:

• The patients had be diagnosed with autoimmune pulmonary alveolar proteinosis through pathology or bronchial alveolar lavage fluid (BALF).
• The patients are old than 18 year.
• Every patient had a complete medical history, chest HRCT, pulmonary function and arterial blood gas analysis.
• The patients have high level antibody of GM-CSF in serum or BALF.

You may not qualify if:

• The patients had a congenital or secondary pulmonary alveolar proteinosis.

Sponsors & Collaborators

• Shanghai Pulmonary Hospital, Shanghai, China: lead

Study Sites (1)

Shanghai pulmonary hospital

Shanghai, Shanghai Municipality, 200433, China

Location

Related Publications (1)

• Bai JW, Huang JN, Shi SY, Ge A, Lu HW, Sun XL, Gu SY, Liang S, Cheng KB, Tian XL, Xiao YL, Xu KF, Xu JF. Updated severity and prognosis score of pulmonary alveolar proteinosis: A multi-center cohort study in China. Front Med (Lausanne). 2023 Feb 7;10:1058001. doi: 10.3389/fmed.2023.1058001. eCollection 2023.

  PMID: 36824611 DERIVED

MeSH Terms

Conditions

Pulmonary Alveolar Proteinosis

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases

Study Officials

• Xinlun Tian, Dr

  Peking Union Medical College Hospital

  PRINCIPAL INVESTIGATOR

• Yonglong Xiao, Dr

  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief of Respiratory and Critical Care Medicine

Study Record Dates

• First Submitted: August 11, 2020
• First Posted: August 18, 2020
• Study Start: January 1, 2020
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: March 9, 2022

Record last verified: 2022-03

Locations

CN (1)